Evidence map›Paper›PMID 40775073›Full record

ArticleJournal of cancer research and clinical oncology2025

Comparison of TACE alone versus TACE combined with synchronous ablation for neuroendocrine neoplasms with liver metastases.

Sun Huiyi, Wang Feihang, Yav Sothea, Zhao Danyang, Huo Zihao, Shuai Junqi, Yan Zhiping, Chen Yi, Liu Liang, Wang Wenquan and 2 more

Erratum issuedAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors.

Sun HuiyiDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Wang FeihangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Yav SotheaRadiology Department, Preah Ketmealea Hospital, Phnom Penh, Cambodia.
Zhao DanyangDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Huo ZihaoDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Shuai JunqiShanghai Institute of Medical Imaging, Shanghai, 200032, China.
Yan ZhipingDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Chen YiDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Liu LiangDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Wang WenquanDepartment of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Ji YuanDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China.
Liu LingxiaoDepartment of Interventional Radiology, Zhongshan Hospital, Fudan University, Shanghai, 200032, China. liulingxiao2022@163.com.

Funding

National Key R&D Program of China and National Health Commission Capacity Building And Continuing Education Center GWJJ2022100303
6 · The paper itself

Abstract

objectiveTo compare the efficacy and safety between thermal ablation combined with synchronous TACE and TACE in patients with liver metastasis of neuroendocrine tumors of different pathologic grades and different primary sites.

methodsA retrospective analysis was performed on patients with liver metastases of neuroendocrine tumors in this study. The patients were divided into simultaneous ablation group and TACE group according to treatment mode and subgroups. The endpoints of prognosis were progression-free survival (PFS) and overall survival (OS).

resultsA total of 108 patients with neuroendocrine tumors were collected, including 46 patients in the simultaneous ablation group and 62 patients in the TACE group. According to WHO classification, 21 patients with G1 grade, 55 patients with G2 grade and 32 patients with G3 grade were included. The median OS and the median PFS showed no statistically significant differences between the TACE group and the simultaneous ablation group. Among G2 stage, the TACE group and the synchronous ablation group showed no difference in the median OS but statistically difference in the median PFS. For G1&2 stage patients, synchronous ablation showed longer median PFS than TACE. In pNET patients, although median OS showed no significant difference between the two groups, the synchronous ablation group achieved longer median PFS compared to the TACE group. Both the TACE group and the synchronous ablation group showed improved median OS in G1&2 stage patients relative to G3 stage patients.

conclusionsSimultaneous ablation can delay disease progression in patients with liver metastasis of neuroendocrine tumors to a certain extent, and has a good safety, especially for patients with liver metastases of neuroendocrine tumors of intermediate or low grade or pancreatic origin.

Indexed as

Chemoembolization, TherapeuticLiver NeoplasmsNeuroendocrine TumorsAdultAgedCombined Modality TherapyFemaleHumansMaleMiddle AgedPrognosisProgression-Free SurvivalRetrospective StudiesComparative analysisLiver metastases of neuroendocrine tumorsPathological gradingSynchronous ablationTransarterial chemoembolization

Identifiers

PMID40775073
PMCPMC12331546

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.